Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Adult growth hormone deficiency treatment with a combination of growth hormone and insulinlike growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case report | Braverman et al. Journal of Medical Case Reports 2010 4 305 http www.jmedicalcasereports.eom content 4 1 305 JOURNALOF medical ÌỤr case REPORTS CASE REPORT Open Access Adult growth hormone deficiency treatment with a combination of growth hormone and insulinlike growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels a case report Cr ì D Dm mr m o z A 1 r r s f 2 I I KỲ I IR s m l A3 c A -I z-k I Z 1 s Z J 13 I H n r 11_I N z-k z- 4 h ỉ m rzT l I s Z 1 I Z t s z 5 tric R Braverman Abdalla Bowirrat Uma J Damle Swetna Yeldandi inomas JH Chen Margaret Iviadigan Mallory Kerner3 Stanley X Huang3 Stella Savarimuthu3 Kenneth Blum3 5 6 Abstract Introduction Adult Growth hormone Deficiency is a well known phenomenon effecting both males and females. Adult Growth Hormone Deficiency is marked by a number of neuropsyehiatrie cognitive performance cardiac metabolic muscular and bone symptoms and clinical features. There is no known standardized acceptable therapeutic modality to treat this condition. A recent meta-analysis found that after 16 years of Growth Hormone replacement therapy a large proportion of the patients still had Growth Hormone associated symptoms especially related to executive functioning. A major goal is to increase plasma levels of both insulin-like growth factor insulin-like growth factor-1 and insulin-like growth factor binding protein 3. Case Presentation We report a case of a 45-year-old caucasian woman with early ovarian failure for 2 years and amenorrhea since the age of 43 who presented with Adult Growth Hormone Deficiency and an IGF-1 of 126 ng mL. Since her insulin-like growth factor-1 was lowest at 81 ng mL she was started on insulin-like growth factor-1 Increlex at 0.2 mg at bedtime which immediately raised her insulin-like growth factor-1 levels to 130 ng mL within 1 month and 193 ng mL 249 ng mL and 357 ng mL after 3 4 and 5 months respectively thereafter. Her
